文献速递瓣膜外科

新型带支架牛心包主动脉瓣生物瓣(Avalus)的安全性、有效性与血流动力学表现

Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis.
PubMed 文献 · Eur J Cardiothorac Surg · 2017-01-01

PERIGON关键性研究为前瞻性、非随机、多中心试验,纳入有症状的中重度主动脉瓣狭窄或慢性重度主动脉瓣反流患者(n=686,459.5瓣年)。植入Avalus瓣后1年生存率96.4%,瓣膜相关血栓栓塞、瓣膜血栓、全部及主要瓣周漏、感染性心内膜炎的线性化率均低于2倍客观性能标准(OPC),但全部及主要出血的线性化率≥2倍OPC。

要点

  • Avalus瓣植入后1年生存率96.4%,功能恢复良好,血流动力学在预期范围内。
  • 瓣膜相关血栓栓塞、瓣膜血栓、瓣周漏及心内膜炎的线性化率均低于2倍OPC。
  • 全部及主要出血的线性化率≥2倍OPC,可能与长期抗凝及随访时长有关。

核心结论

  • Avalus瓣总体安全性和临床有效性良好,但全部及主要出血的线性化率≥2倍OPC。
  • 全部及主要出血率偏高可能与非瓣膜适应证长期抗凝及本队列随访时长有关。

研究设计与样本

  • PERIGON关键性试验为前瞻性、非随机、多中心研究,纳入有症状中重度主动脉瓣狭窄或慢性重度主动脉瓣反流患者(n=686)。
  • 分析要求至少150例随访至1年且至少400瓣年,实际瓣年总数为459.5。

主要发现

  • 随访1年(n=270)生存率为96.4%。
  • 死亡及瓣膜相关血栓栓塞、瓣膜血栓、全部及主要瓣周漏、心内膜炎的线性化率均<2×OPC。
  • 全部及主要出血的线性化率≥2×OPC。

关键数值与推荐

  • 主要分析以EN ISO 5840:2009的OPC比较植入后>30天的瓣膜相关事件线性化率。
  • 原假设为真实线性化事件率的上95%置信界≥2×OPC,拒绝原假设即表明事件率低于可接受水平。

临床怎么用

  • 对有症状中重度主动脉瓣狭窄或慢性重度主动脉瓣反流患者,Avalus瓣可作为生物瓣选择,但需关注出血风险。
  • 术后应评估长期抗凝适应证及出血风险,权衡抗凝策略。

局限性

  • 原文摘要未报告具体局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We assessed the safety, effectiveness and haemodynamic performance of a new bovine stented aortic valve bioprosthesis (Avalus™). METHODS: The PERIGON Pivotal Trial is a prospective, non-randomized, multicentre study. Subjects had symptomatic moderate or severe aortic stenosis or chronic, severe aortic regurgitation. Death, valve-related adverse events (AEs), functional recovery and haemodynamic performance were assessed at discharge, 3-6 months and 1 year. The primary analysis compared 'late' (>30 days post-implant) linearized rates of valve-related thromboembolism, thrombosis, all and major haemorrhage, all and major paravalvular leak (PVL) and endocarditis after implantation with objective performance criteria (OPC) for AEs, in accordance with EN ISO 5840:2009. We hypothesized that the upper 95% confidence bounds of the true linearized AE rates would be ≥ 2 × OPC; rejection of the null hypothesis would demonstrate that these rates were below acceptable rates. The analysis was required to include at least 150 patients followed to 1 year and 400 valve-years. Kaplan-Meier survival analysis was also performed. RESULTS: Total number of valve-years was 459.5 (n = 686). Linearized rates were <2 × OPC for death and valve-related thromboembolism, valve thrombosis, all and major PVL, and endocarditis, but ≥2 × OPC for all and major haemorrhage. Survival at 1 year (n = 270) was 96.4%. Patients showed good functional recovery, and haemodynamic performance was within expected range. CONCLUSIONS: This analysis demonstrated a good safety profile and clinical effectiveness of the Avalus valve except for bleeding rates. The linearized rates of all and major haemorrhage may be related to long-term anticoagulation for non-valvular indications and the length of follow-up of this cohort. TRIAL REGISTRATION: NCT02088554 (www.clinicaltrials.gov).

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Klautz RJM, Kappetein AP, Lange R, et al. Safety, effectiveness and haemodynamic performance of a new stented aortic valve bioprosthesis. Eur J Cardiothorac Surg. 2017. PMID: 28475690. doi:10.1093/ejcts/ezx066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。